A. Holm et al., Fluticasone propionate aqueous nasal spray reduces inflammatory cells in unchallenged allergic nasal mucosa: Effects of single allergen challenge, J ALLERG CL, 107(4), 2001, pp. 627-633
Background: Topical corticosteroid therapy reduces symptoms and nasal mucos
al inflammatory cells in patients with allergic rhinitis. Usually patients
are advised to start their medication (1 week) before the beginning of the
pollen season. The effect of pretreatment with a topical corticosteroid on
unchallenged nasal mucosa is not well documented.
Objectives: The purpose of this study was to investigate, in a double-blind
, placebo-controlled study, the effect of 6 weeks' pretreatment with 200 mu
g twice daily fluticasone propionate on nasal symptoms and inflammatory cel
l numbers after nasal allergen provocation in patients with seasonal allerg
ic rhinitis.
Methods: Nineteen patients with grass pollen-induced allergic rhinitis were
treated for a 6-week period out of the grass pollen season. After completi
ng the treatment period, patients were challenged with grass pollen. Nasal
mucosal biopsy specimens were taken 5 times in every patient. In nasal muco
sa changes in numbers of T cells, B cells, mast cells, eosinophils, macroph
ages, and Langerhans' cells were investigated.
Results: After 4 weeks of treatment but before allergen provocation, signif
icantly fewer epithelial Langerhans' cells, macrophages, mast cells, T cell
s, and eosinophils were found in the fluticasone propionate group compared
with those found in the placebo group. In the lamina propria significantly
fewer Langerhans' cells and eosinophils were found in the fluticasone propi
onate group. Cell influx in nasal mucosa after allergen provocation was sig
nificantly inhibited in the fluticasone propionate group compared with that
in the placebo group for epithelial Langerhans' cells, mast cells, macroph
ages, and T cells and for lamina propria eosinophils, mast cells, Langerhan
s' cells, macrophages, and T cells.
Conclusions: Fluticasone propionate is effective in reducing early- and lat
e-phase nasal symptoms. Topical corticosteroid treatment reduces inflammato
ry cells in unchallenged nasal mucosa.